AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alvotech reported a 420% revenue growth in 2024 and guides approximately 20% growth for 2025, with a revised full-year revenue outlook of $570 million to $600 million. Q3 licensing revenues were $81 million, supporting a 69% gross margin. The company holds a strong market position in the US and EU, but faces challenges with FDA compliance and a temporary loss in product revenues.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet